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Fibromuscular dysplasia (FMD) is an arteriopathy associated with hypertension, stroke and
myocardial infarction, affecting mostly women. We report results from the first genome-wide
association meta-analysis of six studies including 1556 FMD cases and 7100 controls. We
find an estimate of SNP-based heritability compatible with FMD having a polygenic basis, and
report four robustly associated loci (PHACTR1, LRP1, ATP2B1, and LIMA1). Transcriptome-wide
association analysis in arteries identifies one additional locus (SLC24A3). We characterize
open chromatin in arterial primary cells and find that FMD associated variants are located in
arterial-specific regulatory elements. Target genes are broadly involved in mechanisms
related to actin cytoskeleton and intracellular calcium homeostasis, central to vascular
contraction. We find significant genetic overlap between FMD and more common cardio-
vascular diseases and traits including blood pressure, migraine, intracranial aneurysm, and
coronary artery disease.
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Cardiovascular disease (CVD) is the primary cause ofmortality in the world. CVD causes ∼18 million deathseach year, of which 85% are due to stroke and myocardial
infarction (MI)1. Renal artery stenosis is a cause of hypertension,
a preventable risk factor for stroke and MI. Renovascular
hypertension results from numerous factors, which include
atherosclerosis or fibromuscular dysplasia (FMD) in ∼10% of
cases2. While atherosclerosis has been widely studied and its
genetic architecture has been well defined, little is known about
the pathogenesis or genetics of FMD. To date, only PHACTR1, a
pleiotropic locus involved in the genetic risk of several cardio-
vascular and neurovascular diseases, has been reported to
associate with FMD3.
FMD occurs predominantly in early middle-aged women
(mean age at diagnosis 46–53 years)4, thus representing a subset
of the population where cardiovascular and neurovascular disease
present differently depending on sex5,6. FMD is an idiopathic,
segmental, non-atherosclerotic disease of the arterial walls, lead-
ing to stenosis of small and medium-sized arteries, often asso-
ciated with dissection, aneurysm, and in some cases arterial
tortuosity4,7–9. The most frequent form of FMD is multifocal,
which is characterized by multiple stenoses occurring in the same
artery (so called “string of beads” due to classic angiographic
appearance), and accounts for 70–80% of cases4. Further mention
of FMD in the current report will refer to the multifocal type.
Diagnosis is often made incidentally on imaging, as part of an
investigation to elucidate early onset and/or resistant hyperten-
sion, following a stroke event or spontaneous coronary artery
dissection, a form of acute MI associated with female sex as
well10. Based on angiographic examination of renal arteries in
kidney donor cohorts the estimated prevalence of FMD is ~3%11.
In the current study, we report findings from a meta-analysis of
six genome-wide association studies (GWAS) to investigate the
genetic basis of FMD. We report four loci (PHACTR1, LRP1,
ATP2B1, and LIMA1) that are associated with FMD, in addition
to SLC24A3 identified through transcriptome-wide association
studies of arterial transcriptomes from the GTEx database.
Through the integration of open chromatin maps generated by
ATAC-Seq in vascular cells, combined with publicly available
data for arteries, we prioritize variants in associated loci. Using
colocalization with expression quantitative trait loci (eQTLs) and
transcriptome-wide association studies in arteries, we narrow
down potential target genes. We find that risk genes for FMD are
consistently expressed in smooth muscle cells, fibroblasts, and
arterial tissues. These genes are involved in regulatory mechan-
isms related to actin cytoskeleton and intracellular calcium
homoeostasis, a mechanism central to vascular contraction.
Finally, using linkage disequilibrium score regression, we report
an estimate of single nucleotide polymorphism (SNP)-based
heritability compatible with FMD having a polygenic basis, and
an important genetic overlap with blood pressure, migraine,
intracranial aneurysm, and coronary artery disease (CAD).
Results
Meta-analysis of six genome-wide association studies reveals
four risk loci for FMD. We tested ∼5.5 million common genetic
variants (MAF > 0.01), including those on the X chromosome, in
six case control studies from Europe and the United States
totalling 1556 cases and 7100 controls, all of European ancestry
(Supplementary Table S1). Individual studies were adjusted for
sex, the first five principal components, and genomic control.
Using LD score regression12, we found evidence for a polygenic
feature for FMD with an estimated SNP-based heritability (h2) on
a liability scale of 0.43 (standard error: 0.14, estimated prevalence
of 3% in the general population).
Four loci were associated with FMD at genome-wide
significance (Fig. 1a, Supplementary Fig. S1, Supplementary
Table S2). We replicated the previously identified PHACTR1
locus on chromosome 6 (SNP rs9349379, OR= 1.44,
P= 5 × 10−15) and reported three additional loci: LRP1
(rs11172113, OR= 1.34, P= 2 × 10−10), LIMA1 (rs7301566,
OR= 1.29, P= 4 × 10−9) and ATP2B1 (rs2681492, OR= 1.43,
P= 2 × 10−8, Table 1, Supplementary Table S2). All lead SNPs
showed consistent directions of effects and lacked evidence for
heterogeneity (Table 1). Despite mapping to the same chromo-
some, LIMA1, LRP1 and ATP2B1 loci are fully independent and
map to positions 50.5, 57.5 and 90.1 megabases on chromosome
12, respectively. A GWAS in women only (1421 cases, 5724
controls) identified the same four loci, with comparable effect
sizes and levels of significance (Supplementary Table S2). Given
the small number of FMD cases in men (N= 135), a GWAS in
men only was not conducted.
To address the limitation of SNP-based GWAS, which captures
the effects of single variants and may miss the combined mild
effects of several SNPs in a gene, we performed gene-based
association analyses using MAGMA13, as implemented in
FUMA14. We identified five genes from two of the previously
identified loci to be associated with FMD (PBonf.Adj < 0.05)
(Supplementary Table S3). These included four genes at the
LIMA1 locus (ATF1, P= 4 × 10−7, GPD1, P= 5 × 10−7, CERS5,
P= 1 × 10−6, LIMA1, P= 2 × 10−6) and ATP2B1
(P= 5 × 10−7). All genes were located in the vicinity of the 4
loci we identified using SNP-based GWAS, and no additional
genes were identified using the gene-based approach.
FMD-associated variants are likely to regulate gene expressions
of nearby genes in arterial tissues. We queried the GTEx data-
base for eQTL association (v8 release)15 and found the lead SNPs
in FMD loci to be top eQTLs of at least one gene in one or more
of the three arterial tissues available (Fig. 2a, Supplementary
Table S4). Top eQTL associations linked lead variants to the
closest gene at PHACTR1, LRP1 and ATP2B1 loci (Fig. 2b, d, h),
with a high probability (100%, 100% and 98.3%, respectively) of
colocalization between FMD and tibial artery eQTL association
signals (Fig. 2c, e, i). FMD risk alleles were associated with higher
expression of PHACTR1 and LRP1 and lower expression of
ATP2B1 in tibial artery tissue (Fig. 2b, d, f). We note that the
expression of ATP2B1 antisense transcript (ATP2B1-AS) was also
regulated by lead SNPs at the ATP2B1 locus in tibial artery
samples, also with a high probability (96.6%) of colocalization
(Supplementary Fig. S2). At the LIMA1 locus, several genes were
associated with the lead variant in artery tissues (Fig. 2a, f), but
none of the eQTL signals colocalized definitively with the FMD
association signal (Fig. 2g, Supplementary Fig. S2).
Interestingly, a query of transcriptome sequencing data
obtained in primary dermal fibroblasts cell lines from 83 FMD
patients16 found rs9349379 to correlate with PHACTR1 expres-
sion (P= 0.01), confirming the association observed in GTEx
artery tissue (Supplementary Fig. S3).
Transcriptome-wide association study in arteries. We con-
ducted a transcriptome-wide association study (TWAS) using the
FUSION software17, and gene expression models calculated from
artery eQTL analyses from GTEx (v7 release) combining
expression data from tibial, aorta and coronary arteries (Fig. 1c,
d). We found significant association between genetically predicted
expression of PHACTR1 (P= 1.1 × 10−11, tibial and aorta), LRP1
(P= 2.7 × 10−10, tibial) and FMD (Table 2, Fig. 1c, d, Supple-
mentary Table S5). Genetically predicted expressions of ATP2B1
and ATF1 were suggestively (FDR < 0.05) associated with FMD
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(Supplementary Table S5). TWAS in tibial artery revealed
SLC24A3 to associate with FMD (P= 6 × 10−7, Fig. 1c, d). Of
note, SLC24A3 showed nominal significance in the gene-based
analysis (P= 2 × 10−3), and it overlaps two independent and
suggestive signals (lead SNP: rs2424245, P= 4.0 × 10−6, sec-
ondary SNP: rs6046121, P= 4 × 10−4, correlation r2 < 0.01,
Supplementary Fig. S4). FMD risk alleles of both variants asso-
ciated with lower SLC24A3 expression in tibial artery and aorta
(Supplementary Fig. S4).
FMD-associated loci are located in regulatory elements in
arteries and VSMCs. To gain insights into the potential reg-
ulatory function of the topmost associated SNPs with FMD, we
generated open chromatin profiles using ATAC-Seq in human
carotid artery-derived primary cells (two VSMCs and two ECs
primary cell lines), human coronary artery-derived cells (one
VSMC and one EC primary cell line), human dermal (two cell
lines) and cardiac fibroblasts (one cell line). We also reanalysed
published data obtained using ATAC-Seq of healthy coronary
arteries18. Using a common pipeline analysis, we obtained
177,015–196,272 peaks from cultured human VSMCs,
120,577–137,779 from ECs and fibroblasts, and 54,622–70,855
peaks from human coronary arteries (Supplementary Fig. S5a).
Global correlation and principal component analyses showed that
open chromatin regions of fibroblasts and VSMCs cluster toge-
ther, whereas ECs and artery samples form separate clusters
(Supplementary Fig. S5b, c). Using the GREGOR algorithm19, we
Fig. 1 SNP-based and transcriptome-wide association analyses. a Manhattan plot representation of SNP-based association analysis in FMD. −log10 of
association P value (from a two-sided Wald test) is represented on the y-axis, genomic coordinates on the x-axis. Name of lead SNPs with P value
≤ 5 × 10−8 are indicated. b Manhattan plot representation of Transcriptome-wide association analysis (TWAS) in FMD with tibial artery (square dots),
aorta (round dots) and coronary artery (triangle dots) gene expression models. −log10 of association P value is represented on the y-axis, genomic
coordinates on the x-axis. Name of genes with Bonferroni corrected P value ≤ 0.05 are indicated. c Volcano plot representation of FMD TWAS. TWAS Z-
score is represented on the x-axis, −log10 of TWAS P value on the y-axis. The dashed line represents the threshold for significance adjusted for multiple
testing. Name of genes with Bonferroni adjusted P value < 0.05 are indicated.
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found that associated variants from FMD GWAS (lead SNPs with
P < 10−4, and their proxies at r2 ≥ 0.7, Supplementary Data 1)
were enriched in open chromatin peaks of artery tissues (average
1.5-fold enrichment, 10−2 < P < 7 × 10−2, Supplementary
Fig. S5d). To account for a potential effect of the number of peaks
on SNP enrichment, which is lower in the arterial samples we
analysed (Supplementary Fig. S5c), we restricted the analysis to
the top scoring 50,000 peaks in SMCs, ECs, dermal fibroblasts
and arteries, which confirmed the initial finding (Supplementary
Fig. S5d). Globally, we found that artery-specific ATAC-Seq peaks
are overrepresented in the vicinity of genes involved in contractile
fibres and muscle system processes (Supplementary Fig. S5e, f).
We annotated the credible sets of variants, those representing
>95% of cumulated posterior probability to cause the association
at each locus, with overlapping open chromatin regions from
these ATAC-Seq datasets (Table 3). At the PHACTR1 locus, the
lead variant (rs9349379) was located in a chromatin region open
in arterial tissue but not accessible in VSMCs, fibroblasts, or ECs.
This variant also overlapped with well-defined enhancer marks in
arterial tissue and was strongly supported as the causal variant in
this locus (Fig. 3a, b). The lead variant (rs11172113) in LRP1
overlapped with open chromatin peaks in arterial tissue, primary
VSMCs and fibroblasts, but not primary ECs (Fig. 3c, d). Strong
enhancer and promoter marks were also present in arterial tissue
around this variant, which mapped 5 kb downstream of LRP1
promoter and is the most likely causal variant. At the LIMA1
locus, the variant with the highest posterior probability of being
causal, rs7301566, overlapped a region active in arteries, VSMCs,
and fibroblasts and also strong enhancer marks in arteries
(Fig. 3f). Three other variants (rs4459386, rs10783342,
rs12815871) also overlapped marks indicating potential regula-
tory properties (Fig. 3f, Table 3). Finally, the ATP2B1 locus
included three highly associated and potentially causal variants
(rs11105352, rs11105353 and rs11105354, Fig. 3g), which all
overlapped a small open chromatin peak specifically observed in
arterial tissue, and an enhancer-specific H3K4me1 histone mark
(Fig. 3h).
FMD potential target genes are expressed in VSMCs and
fibroblasts. We assessed the expression of FMD potential target
genes (Table 2) by leveraging results from pre-existing tran-
scriptomics datasets. Inquiry of the mouse aorta single-cell RNA-
Seq data20 showed that potential target genes were mostly
expressed in VSMC and fibroblasts clusters. (Supplementary
Fig. S6). Based on RNA-Seq dataset from GTEx, we found that
FMD potential target genes were robustly expressed in tibial
artery tissue, while SLC24A3 presented a lower expression in
arterial samples of women, compared to men (P= 1 × 10−5,
Supplementary Fig. S7).
FMD risk loci and associations with blood pressure and
hypertension. All FMD top loci were previously associated with
at least one trait related to blood pressure, with the same alleles
being associated with increased FMD risk and higher blood
pressure/hypertension risk (Fig. 4a). Hypertension is reported in a
large proportion of patients with FMD in general, and in the
majority of FMD cases in this study (51–85%, Supplementary
Table S1). To test for hypertension as a potential confounder
driving the observed association signals, we conducted both
stratified and adjusted analyses for hypertension status for the
GWAS lead variants in the two largest studies: the French and the
UM-MGI/CCF studies (Supplementary Table S6). Adjustment for
hypertension status marginally modified the effects sizes and level
of significance of the associations with FMD at all four loci,
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Fig. 2 Tissue-wide eQTL signals near FMD loci. a Heatmap representation of eQTL signals at FMD loci. GTEx v8 database was queried for significant
eQTLs using the lead variant rsID number. All genes identified as positive eQTL in at least one tissue were selected to calculate eQTL associations in all
tissues available in this database. The negative logarithms (−log10) of the eQTL association P values are represented in a blue–red colour scale. b, d, f, h
Violin plots representing normalized expression of PHACTR1 (b), LRP1 (d), ATF1 (f) and ATP2B1 (h) by genotype of lead SNPs in tibial artery (b, d, h) and
aortic tissue (f). Plots illustrate the best eQTL association in arterial tissue for the lead SNP at each locus. eQTL unadjusted P values were obtained from
testing that the slope of linear regression model between genotype and expression deviates from 0 using a two-sided Wald test. FMD risk allele is on the
left. c, e, g, i Colocalization plot of FMD association (x-axis, log scale of genetic association P value) with tibial artery (c, e, i) and aortic tissue (g) eQTL
association (y-axis, log scale of P value) at each locus. Dot colour represents the LD r2 with the lead variant in 1000G European samples. FMD lead variant
is highlighted (Diamond shape, purple). Approximate Bayes Factor Posterior Probability (PP.abf) for the two traits to share a common causal variant (H4
coefficient) is indicated.
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study). Given the large proportion of hypertension, both in the
cases and the controls of the French study, associations with FMD
were only observed in the larger stratum of hypertensive patients.
However, all four loci showed significant association with FMD
both in hypertensive and non-hypertensive individuals in the
UM-MGI/CCF case control study. We also looked up the lead
variants significantly associated with systolic blood pressure
(SBP) in a recent meta-analysis GWAS of blood pressure traits21.
In addition to the three FMD loci (PHACTR1, LIMA1 and
ATP2B1), one variant near FHL5 on chromosome 6 showed
evidence for suggestive association with FMD (P= 2 × 10−5,
Supplementary Data 2).
FMD-associated loci are pleiotropically associated with multi-
ple vascular diseases. In addition to blood pressure, PHACTR1,
LRP1 and SLC24A3 have been previously associated with
migraine, involving identical risk alleles (Fig. 4a)22. PHACTR1
and LRP1 were also associated with cervical artery dissection and
spontaneous coronary artery dissection, and LRPI was addition-
ally associated with abdominal aortic aneurysm (Fig. 4a)23–25.
PHACTR1 and ATP2B1 were associated with CAD and MI, while
LRP1 was suggestively associated to CAD, and in all three loci, the
CAD risk alleles were the opposite of those associated with FMD
(Fig. 4a)26. Colocalization of FMD association signals with the
most relevant traits (Fig. 4b, Supplementary Table S7), in addition
to the comparison of FMD TWAS in arteries with other diseases
(Fig. 4c), suggested that the same variants are likely to be causal in
FMD, cervical artery dissection, migraine, and CAD.
Genetic relationships between FMD and more common car-
diovascular diseases and traits. In light of the important number
of diseases in which FMD loci and genes are involved, we used
LD score regression27 to calculate the genome-wide correlation
between FMD and other diseases and traits (Fig. 5a, b, Supple-
mentary Table S8). As expected, FMD was positively correlated
with hypertension (rg= 0.36, P= 2 × 10−7), systolic (rg= 0.43,
P= 2 × 10−9) and diastolic (rg= 0.37, P= 1 × 10−8) blood
pressure, and pulse pressure (rg= 0.35, P= 2 × 10−8). FMD also
correlated positively with migraine (rg= 0.28, P= 8 × 10−4),
intracranial aneurysm (pooled ruptured and unruptured, rg=
0.36, P= 2 × 10−5), aneurysmal subarachnoid haemorrhage
(rg= 0.35, P= 2 × 10−4), and cervical artery dissection, although
this latter did not survive correction for multiple testing (rg=
0.67, P= 3 × 10−2). No significant correlation with any of the
kidney function related traits was observed (Fig. 5b, Supple-
mentary Table S8). To determine whether the correlation of FMD
with blood pressure, an important risk factor for several CVDs,
may influence the genetic correlations we estimated with FMD,
we conditioned FMD association on the genetic association with
SBP obtained from the meta-analysis GWAS21 using mtCOJO. Of
note, the association of top loci with FMD remained significant
after this conditioning on SBP genetics (Supplementary Table S9).
Interestingly, mtCOJO results revealed a significant negative
genetic correlation of FMD with CAD (rg=−0.31,
P= 5 × 10−5) and MI (rg=−0.30, P= 4 × 10−4) (Fig. 5c,
Supplementary Table S10), indicating that this opposite genetic
relation between FMD and CAD/MI is not mediated by common
loci between FMD and SBP. The genetic correlation of FMD with
migraine was only marginally affected by conditioning on SBP
genetics (rg= 0.33, P= 4 × 10−4). On the other hand, the genetic
correlations with intracranial aneurysm, subarachnoid haemor-
rhage, and low-density lipoprotein cholesterol levels were less
significant after conditioning on SBP genetics, indicating that
these correlations with FMD are in part due to genetic associated
loci shared between FMD and SBP (Fig. 5c, d, Supplementary
Table S10). The genetic correlation results were unchanged when
we conducted the analyses after removing the SNPs at the top
FMD-associated loci (Supplementary Tables S11–12).
Discussion
Our study is the most comprehensive genetic investigation to date
dedicated to FMD, a non-atherosclerotic arterial disease primarily
diagnosed in middle-aged women with few classical cardiovascular
risk factors. Key findings from our study include: (i) identification
of risk loci and/or genes using single variant GWAS and TWAS in
arteries; (ii) through integration of newly generated and publicly
available annotation datasets we narrowed down the list of causal
variants in most risk loci; (iii) FMD risk genes showed consistent
expression in arterial tissue, mostly in VSMCs and fibroblasts. (iv)
We found an important genetic overlap between FMD and blood
pressure, not only for the top associated loci and genes but also at
the GWAS level, although hypertension is unlikely to confound
the genetic association with FMD at the 4 loci described. (v) FMD
shared genetic bases and potentially biological mechanisms with
some but not all cardiovascular and neurovascular diseases.
The genetic investigation of FMD has been inconclusive for
decades due to the lack of a clear genetic model. Here we provide
an estimated SNP heritability of ∼0.43 in its multifocal form,
suggesting a polygenic basis of this neglected and underdiagnosed
vascular disease. Efforts to establish large cohorts of FMD
patients to conduct well-powered genetic studies are very recent
and follow the increased awareness about its relatively high pre-
valence (∼3%) in asymptomatic individuals28.
Our study identified four loci contributing to FMD genetic risk.
Most of these loci were previously shown to be involved in
multiple vascular diseases. LRP1 is a risk locus for pulse
pressure29, migraine22, aortic abdominal aneurysm30, and was
recently reported for spontaneous coronary artery dissection24,31
involving the same risk allele for FMD that correlates with higher
gene expression. However, the opposite allele was reported to
Table 2 Transcriptome-wide association analysis in arterial tissues.
Locus information Gene information TWAS
Lead SNP EA EAF OR P Gene Chr: start-top Best tissue P Padj Z
rs9349379 A 0.63 1.44
(1.31–1.57)
5 × 10−15 PHACTR1 6:12717893-
13288645
Aorta 3 × 10−13 4 × 10−9 7.3
rs11172113 T 0.62 1.34
(1.22–1.46)
2 × 10−10 LRP1 12:57522276-
57607134
Tibial 2 × 10−10 3 × 10−6 6.4
rs2424245 T 0.86 1.37
(1.19–1.57)
4 × 10−6 SLC24A3 20:19193290-
19703581
Tibial 6 × 10−7 0.01 −5.0
The table P values (P) and Z scores (Z) obtained in the trancriptome-wide association based on gene expression models from GTEx in tibial artery, aorta and coronary artery and GWAS. For each gene,
only the best TWAS association is shown. All genes with Bonferroni adjusted P value below 0.05 are reported. FMD GWAS association for the best SNP in the locus is indicated.
EA effect allele, EAF effect allele frequency, OR odds ratio, P: P value, Chr Chromosome, Padj. Bonferroni corrected P-value for TWAS association.
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Fig. 3 Visualization of potential causal variants genes at FMD-associated loci. a, c, e, g LocusZoom representation of FMD-associated loci (a PHACTR1
locus, c LRP1 locus, e LIMA1 locus, g ATP2B1 locus). Dot colour indicates LD of each variant with the highlighted lead variant (purple diamond). Position and
rsID of putative causal variants are indicated. P value of genetic association is represented on the y-axis (negative log scale) (b, d, f, h) Genome browser
visualization of ATAC-Seq/Histone-ChIP read densities (in reads/million, r.p.m.) in the regions surrounding putative causal variants. b PHACTR1 locus. d
LRP1 locus. f LIMA1 locus. h ATP2B1 locus. Grey line highlights variant position.
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-021-26174-2 ARTICLE
NATURE COMMUNICATIONS |         (2021) 12:6031 | https://doi.org/10.1038/s41467-021-26174-2 | www.nature.com/naturecommunications 7
increase the risk for MoyaMoya disease32 and suggestively for
CAD26. LDL receptor protein 1 (LRP1) is a widely studied
molecule that plays important roles in multiple cellular processes
relevant to FMD such as the remodelling of the extracellular
matrix and VSMCs migration33, among others. LRP1 function in
VSMCs is mediated partly by the modulation of calcium signal-
ling, leading to deficient vasoconstriction in VSMC-specificLrp1-
deficient mice34.
Interestingly, two of the genes we identified are involved in
intracellular calcium homoeostasis, a highly relevant molecular
mechanism for vascular contractility and vasodilation. ATP2B1
encodes an ATP-dependent calcium channel specialized in the
exportation of calcium ions from the cytoplasm to the extra-
cellular space. ATP2B1 is a well-established hypertension and
blood pressure locus, where the same alleles increase the risk for
FMD and hypertension (Fig. 4). Mice lacking Atp2b1 specifically
in VSMCs exhibit hypertension, higher intracellular calcium
levels and increased sensitivity to nicardipine, a calcium channel
blocker35,36. On the other hand, SLC24A3, which we identified
through the TWAS analyses in arteries, encodes a transmembrane
sodium/potassium/calcium exchanger also involved in calcium
homoeostasis37. The relevance of impaired vasodilation and/or
enhanced vasoconstriction in FMD pathogenesis is supported by
our recent study where we reported an enrichment among FMD
patients for rare loss-of-function mutations in the gene encoding
the receptor for prostacyclin, a major vasodilator hormone38. In
line with these findings, impaired dilation of arteries in response
to sublingual glyceryl trinitrate, a proxy for VSMC dysfunction,
was reported in FMD patients, including in arterial segments
clinically unaffected by the disease39.
Several potential target genes were identified in the chromo-
some 12 LIMA1 locus, with LIM domain and acting binding 1
(LIMA1) and activating transcription factor 1 (ATF1) genes as the
strongest biological candidates. The role of LIMA1 in actin
dynamics is compatible with a potential role in maintaining cell
shape, a feature lost in FMD-affected VSMCs40. A study descri-
bed a rare frameshift variant in LIMA1 from a family with
inherited low LDL cholesterol, and resistance in diet-induced
hypercholesterolemia has been described in a Lima1-deficient
mouse41. While its specific role in arteries is not known, ATF1 is
a transcriptional effector of the cyclic adenosine monophosphate
pathway, which plays a key role in the regulation of vascular
tone42.
Our study provides robust confirmation of the association with
FMD of PHACTR1, a pleiotropic locus that is involved in a large
number of vascular diseases43,44. The functional annotations, the
colocalization analyses, TWAS in arteries and eQTL results, all
point to rs9349379 as a clear regulator of PHACTR1. The pre-
viously suggested regulation of the endothelin-1 gene (EDN1)43 is
not supported by our results, or those from a subsequent study
that used an identical approach of iPSC induced endothelial
cells45, or yet another study which directly measured endothelin-
1 plasma levels in FMD patients and matched healthy controls16.
The phosphatase and actin-binding protein encoded by
PHACTR1 regulates actin stress fibre assembly and cell motility46,
functions highly relevant to the cellular disorganization that
characterizes VSMCs in FMD-affected arteries40. Further inves-
tigation, especially with in vivo models, is needed to more pre-
cisely define the function of PHACTR1 in the context of the
genetic risk to a diverse panel of CVDs.
Through genetic correlation analyses, we were able to globally
position the genetic basis of FMD among the genetics of more
commonly studied CVDs and traits. We showed that FMD
shares a significant proportion of its genetic basis with hyper-
tension and blood pressure-related traits, not only for the top
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the currently large list of SBP loci in our meta-analysis of GWAS
only revealed one additional suggestive locus near FHL5,
potentially reflecting the limited power of our datasets to detect
additional loci using the existing list of SBP loci. Although we
have demonstrated that hypertension is not a confounding factor
for the associations of FMD top loci, the exact direction of the
relationship between the genetic basis of FMD and hypertension
is challenging to determine given that we only report 4 loci,
compared to >1000 SBP currently reported loci21,29. FMD often
manifests with renovascular hypertension. Although percuta-
neous angioplasty leads to blood pressure normalization in ~40%
of cases, it can also be ineffective, suggesting potential additional
mechanisms leading to hypertension in individuals with FMD47.
Not all patients with FMD present with hypertension, especially
when the disease affects arteries outside the renal bed8. Another
possible explanation of the genetic correlation with SBP could be
the high prevalence of essential hypertension in the general
population, which is a major risk factor for all forms of CVD
where FMD can coexist, including stroke and MI. Further
investigation on FMD aetiology will provide additional insights
into the clinical and genetic relationship of FMD, SBP, and
hypertension.
We showed an expected positive genetic correlation between
FMD and migraine, which is reported by 25–69% of FMD
patients4,8, and cervical artery dissection, which occurs in the
same cerebrovascular beds affected in FMD (i.e., carotid and
vertebral arteries). However, we found little support for shared
genetics with ischemic stroke subtypes despite FMD being fre-
quently diagnosed in the context of a stroke event. On the other
hand, FMD seems to be more genetically related to intracranial
aneurysm and aneurysmal subarachnoid haemorrhage, con-
cordant with the observation that approximately 12–13% of
patients with FMD are found to have intracerebral aneurysms
upon angiographic imaging surveillance4. Stroke due to sub-
arachnoid haemorrhage shares several clinical characteristics with
FMD, mainly a high proportion of younger (<55 years) and more
women among patients, association with blood pressure and
smoking48. Finally, we observed an inverse association between
FMD and CAD/MI both for the top loci and genes, and globally
when FMD association is conditioned on the genetics of SBP. The
elimination of the presence of atherosclerosis as the cause of
stenoses and aneurysms is required for FMD diagnosis, which
may have influenced this negative correlation with a disease
where atherosclerosis is underrepresented. FMD is a disease
Fig. 4 Pairwise trait colocalization of FMD associations. a Associations of FMD loci with other vascular diseases. Variants in LD (r2 > 0.5) with the lead
SNP were used to query GWAS catalogue database (accessed on August 5th 2020), UK BioBank GWAS traits and specific meta-analysis of GWAS for
CAD/MI, stroke, blood pressure and intracranial aneurysms. Two independent lead SNPs were retained for SLC24A3 locus. Overlaps are reported for the
following traits/diseases: hypertension (HTN), pulse pressure (PP), systolic blood pressure (SBP), diastolic blood pressure (DBP), migraine (Mig), cervical
artery dissection (CeAD), spontaneous coronary artery dissection (SCAD), abdominal aortic aneurysm (AAA), MoyaMoya disease (MD), coronary artery
calcification (CAC), coronary artery disease (CAD) and myocardial infarction (MI). Large bubbles indicate association below genome-wide significance for
the corresponding trait (P value of genetic association < 5 × 10−8), smaller bubbles correspond to suggestive signals (P < 1 × 10−5). Red colour indicates
same direction effects of risk alleles compared to the association with FMD, blue colour opposite direction associations. b Heatmap representation of the
approximate Bayes factor posterior probability of FMD and related traits to share a common causal variant at the indicated loci (coefficient H4 of the
colocalization analysis, represented on a white-red colour scale). c Heatmap representation of TWAS Z-Score for FMD-associated genes. TWAS was
performed with tibial artery gene expression models for the indicated traits or diseases (x-axis). Z-scores, represented on a blue-red colour scale, are
shown for all FMD-associated genes in the gene-based and TWAS analyses (y-axis). Illustrations were designed by macrovector/Freepik.
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mostly diagnosed in young to middle-aged women, who are less
prone to develop CAD and MI, which predominantly affects
older men. Whether FMD patients are less likely to develop CAD/
MI later in life, compared to patients of similar clinical char-
acteristics is not known. Endogenous or exogenous female hor-
mones are considered to be protective factors from CAD/MI49,
but are suspected as a potential risk factor in FMD pathogenesis,
given the high proportion of women among patients (80–90%)
and the age of diagnosis of FMD (on average ∼50 years)4. Oes-
trogens stimulate the release of vasodilator mediators such as
nitric oxide and prostacyclin and inhibit the potent vasocon-
strictor endothelin-149. Our study did not point to any direct link
with sex hormone metabolism or regulation, except sex differ-
ences in the level of SLC24A3 transcript expression in women
as compared to men, consistent with the direction of effects of
FMD risk allele. Interestingly, Slc24a3 expression was previously
described as regulated during the oestrous cycle in rodents50.
More knowledge about detailed biological and physiological roles
of both genes are needed to address potential consequences on
artery remodelling in sex and atherosclerosis dependent contexts.
Our work has several limitations. The study has limited power
to fully address the genetic basis of FMD. This is in part due to
underdiagnosis of FMD4 and overall modest sample size. Future
efforts to analyse larger cohorts are expected to permit further
investigation of the relationship of FMD to other vascular dis-
eases, including Mendelian Randomization approaches that
would benefit from higher-powered analysis. Specifically, the
current findings are insufficient to allow an extensive investiga-
tion of the relationship between FMD and hypertension to
address putative causal relationships; the main limitations being
the extremely unbalanced number of established loci that can be
used as instruments (4 loci for FMD as compared to ~800 for
Fig. 5 Genetic correlations between FMD and other traits and diseases. a Genetic correlation obtained using LD Score analyses between FMD and
vascular diseases and traits. HTN hypertension, BP blood pressure, SBP systolic BP (dark blue), DBP diastolic BP, PP pulse pressure, CeAD cervical artery
dissection, IA intracranial aneurysm, all forms, SAH aneurysmal subarachnoid haemorrhage, i.e., ruptured intracranial aneurysm, uIA unruptured
intracranial aneurysm, AS any stroke, AIS any ischaemic stroke, LAS large artery stroke, CES cardioembolic stroke, SVS small vessel stroke, CAD coronary
artery disease, MI myocardial infarction. b Genetic correlation obtained using LD Score analyses between FMD and vascular diseases and metabolic traits.
HDL high-density lipoprotein, LDL low-density lipoprotein, TC total cholesterol, TG triglycerides, ApoA apolipoprotein A, ApoB apolipoprotein B, eGFR
estimated glomerular filtration rate (calculated with creatinine or cystatin), UACR urine albumin to creatinine ratio, BUN blood urea nitrogen, CRP
C-reactive protein. c, d Genetic correlation results after FMD genetic association statistics were conditioned on systolic blood pressure. *Unadjusted P
value of genetic correlation estimated from linkage disequilibrium score regression using a two-sided Wald test is below the multiple testing threshold for
significance (1.6 × 10−3 for 31 tests).
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SBP), with all FMD loci established as having pleiotropic asso-
ciation with blood pressure and several other vascular diseases.
Due to the need for angiographic imaging for the identification of
FMD, it is possible that asymptomatic FMD was present in a
small proportion of control subjects. We compared our genetic
data to available expression datasets in tibial artery, coronary
artery and aorta, but arterial beds most frequently affected by
FMD lesions (renal or carotid artery) would be more appropriate.
Finally, due to very low numbers of non-Europeans individuals in
our studies, we focused our analysis on European ancestry sub-
jects. The study of FMD in diverse ethnic groups will be required
to analyse the trans-ethnic genetic basis of FMD.
In summary, in this first meta-analysis of GWAS for FMD, we
report robustly associated loci and genes and provide several leads
toward understanding biological mechanisms of arterial stenosis
in the absence of atherosclerosis. Further investigation of the
exact biological effects driven by these genes may shed light on
the cause of the higher prevalence of FMD in women and provide
insights into the shared genetic basis between FMD and more
common CVDs and traits.
Methods
Patients and control populations. The meta-analysis included participants of
European ancestry from six studies: ARCADIA8/3C51 GWAS, Mayo Vascular
Disease Biorepository52, DEFINE-FMD study16, ARCADIA-POL53/WOBASZ II54
study, University of Michigan/Cleveland Clinic Foundation (UM/CCF) study31,55
and FEIRI7/ASKLEPIOS56 study. FMD patients presented similar clinical char-
acteristics (Supplementary Table S1) and homogeneous diagnosis, exclusion and
inclusion criteria. Detailed description of the participating cohorts is given below.
ARCADIA. FMD patients were included from the ARCADIA (Assessment of Renal
and Cervical Artery DysplasIA) register, a national FMD registry at the Georges
Pompidou European Hospital, APHP, Paris8. The diagnosis of FMD was estab-
lished using clinical information from the medical history, the interpretation of
angiography and/or computed tomography scan of arterial beds after the exclusion
of other causes of arterial stenosis such as atherosclerosis, Takayasu disease, Ehlers
Danlos syndrome and neurofibromatosis type 1. Given the complexity of the
interpretation of imaging of vascular diseases, a local panel of experts including
clinicians from the departments of hypertension, radiology, vascular medicine and
medical genetics validated the diagnosis. ARCADIA/PROFILE protocol was
approved by the Ile-De-France research ethics committee (Comité de Protection
des Personnes: CPP d’île de France) on 03/04/2009 (ID: 2009-A00288-49).
Three City (3C). The Three-City Study (3C Study) is a population-based long-
itudinal study of the relation between vascular diseases and dementia in persons
aged 65 years and older51. Participants were recruited from three French cities:
Bordeaux (South-West), Dijon (North-East) and Montpellier (South-East). The 3C
Study extended from 1999 to 2012. Participants underwent regular extensive
examination. Examination included measurements of traditional vascular risk
factors (blood pressure, glycaemia, lipids, etc.), cognitive functions, and subclinical
vascular diseases using carotid ultrasound and cerebral magnetic resonance ima-
ging. The study protocol was approved by comité consultatif de protection des
personnes dans la recherche biomédicale Bicêtre Hôpital Bicêtre n°99-28 CCPPRB
approved 10/06/99, 11/03/2003 and 17/03/2006.
Mayo VDB Case Control study. Potential FMD cases and controls were identified
from the Mayo Vascular diseases Biorepository (VDB)52. Electronic health records
of 209 patients including angiographic imaging (computed tomographic, magnetic
resonance or catheter-based angiography) were manually reviewed by clinicians
and the diagnosis was confirmed for 175 patients according to previously reported
criteria4, of whom 169 (83.4% females) had high-density genotyping data following
QC. Controls (n= 1141) were participants without known FMD or atherosclerotic
vascular diseases. The study was approved by the Mayo Clinic Institutional Review
Boards (IRB # 08-008355).
DEFINE-FMD Study. Eligible cases were females with an imaging-confirmed
diagnosis of multifocal FMD and who fulfilled other accepted diagnostic
criteria,4,16. DEFINE-FMD purpose was to establish a library of fibroblasts, DNA,
plasma and serum from patients with FMD and unaffected healthy control sub-
jects. FMD cases were required to have a clinical diagnosis of multifocal FMD that
is confirmed by imaging [computed tomographic angiography (CTA), magnetic
resonance angiography, or catheter-based angiography]. Healthy controls were
matched to FMD cases according to age and sex, required to be receiving ≤2 blood
pressure medications, have a body mass index <35 kg/m2 and to be non-smokers.
Healthy controls underwent physical exam and those with bruits; unexplained
hypertension or other cardiovascular findings were excluded. Exclusion criteria for
all subjects included male gender, unifocal FMD, use of immunosuppressive agents,
major comorbidities, diseases that may confound genetic/genomic analyses (i.e.,
Crohn’s disease, multiple sclerosis, etc.) or any other form of heritable vascular
disease (i.e., Ehlers-Danlos, Marfan, Loeys-Dietz)16. DEFINE-FMD study was
approved by the Human Research Ethics Committee of the Icahn School of
Medicine at Mount Sinai (Study ID: HS#13-00575/GCO#13-1118) and is registered
with ClinicalTrials.gov Identifier: NCT01967511. Patient consent did not involve
the possibility to redistribute biological material and any request should be
addressed to DEFINE-FMD leaders.
ARCADIA-POL. Patients were recruited through the ARCADIA-POL (Assessment
of Renal and Cervical Artery Dysplasia - POLAND) study, a nation-wide Polish
registry for FMD53. From January 2015 until December 2018, 343 patients, women
and men aged more than 18 years were referred from 32 centres in Poland and
were evaluated for suspicion of FMD in the Institute of Cardiology, Warsaw,
Poland. FMD lesions in at least one vascular bed were confirmed in 232 patients
using whole-body angio-computed tomography. We analysed 129 patients for
whom we excluded atherosclerotic stenosis and syndromes where FMD-like lesions
are often observed (eg, Ehlers Danlos, Loeys-Dietz). ARCADIA-Pol study was
approved by Local Ethics Comittee, Institute of Cardiology, IK-NPIA-0021017/
1482/17.
WOBASZ II. We used 298 controls from a randomly ascertained sample from the
WOBASZ II (Multicentre National Population Health Examination Survey) study,
a population-based Polish cohort54. The WOBASZ II study was planned as a cross-
sectional survey of a random sample of Polish residents aged over 20 years. The
selection, using the National Identity Card Registry of the Ministry of Internal
Affairs, was made as a three-stage sampling, stratified according to administrative
units (voivodeships), type of urbanisation (commune), and gender. The study
protocol consisted of a questionnaire used in face-to-face interviews, physical
examination, and blood samples. WOBASZ II was coordinated by the Department
of Epidemiology, Cardiovascular Diseases Prevention and Health Promotion of the
Institute of Cardiology in Warsaw in cooperation with medical universities in
Gdansk, Katowice, Krakow, Lodz, and Poznan. The study was accepted by the Field
Bioethics Committee of the Institute of Cardiology in Warsaw.
University of Michigan-Michigan Genomics Initiative/Cleveland Clinic case
control study. FMD patients were recruited at the UM and/or the Cleveland
Clinic. UM/CCF FMD cases were recruited into an IRB-approved study through a
referral clinic at the UM and through self-referral to the study. The Cleveland
Clinic cases were enroled among consecutive patients seen at a dedicated FMD
referral clinic. Clinical diagnosis of FMD was ascertained by a vascular medicine
specialist after review of diagnostic imaging (computed tomographic, magnetic
resonance or catheter-based angiography) and prior to blood sample collection.
Genomic DNA was isolated from a peripheral blood or saliva sample. The
Michigan Genomics Initiative (MGI) is a program that recruited participants while
awaiting diagnostic, interventional, and surgical procedures. Participants provided
a blood sample for genetic analysis and agreed to link their sample to their elec-
tronic health record and other sources of health information55. Several ICD codes
corresponding to diagnoses of arterial aneurysm, dissection, and non-
atherosclerotic dysplasia and stenosis were excluded, as well as connective tissue
disorders, as previously described31. The hypertension variable was defined as any
ICD code containing the “hypertension” term for MGI controls. The UM/Cleve-
land case control study was approved by each institution’s IRB protocols: The
University of Michigan IRB number is HUM00044507, and the Cleveland Clinic
IRB number is 10-318.
FMD European/International Registry and Initiative (FEIRI). Patients were
enroled through the European/International FMD Registry and Initiative (FEIRI)7.
FMD was defined as the presence of an idiopathic, segmental, non-atherosclerotic,
and noninflammatory stenosis (either with focal or string-of-beads appearance) of
a small- or medium-sized artery in at least 1 vascular bed, documented with CTA,
magnetic resonance angiography, or catheter-based angiography imaging. Patients
with a suspicion of FMD only based on duplex ultrasound were excluded. Patients
whose primary diagnosis was spontaneous coronary artery dissection were not
eligible, even in the presence of extracoronary FMD lesions. Data on demographic
and FMD characteristics were collected through the FMD Registry. All centres
included in FEIRI received approval from the respective local/ national ethics
committees.
Asklepios. The Asklepios Study is a longitudinal population study focusing on the
interplay between ageing, cardiovascular haemodynamics and inflammation in
preclinical CVD56. Participants aged 35–55 years were sampled from the twinned
Belgian communities of Erpe–Mere and Nieuwerkerken. Exclusion criteria were
the presence of atherosclerotic lesions and concomitance with major illness, dia-
betes or conditions precluding accurate haemodynamic assessment. All partici-
pants underwent systematic physical examination during a continuous 2-year
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period, between October 2002 and September 2004 at a single study site in
Erpe–Mere involving: measurement of basic clinical data, blood samples collection,
echocardiographic examination and vascular echography and tonometry mea-
surements. The ethical committee of the Ghent University Hospital approved the
study protocol.
Genome-wide association analyses and meta-analysis. Details on genotyping,
variant calling for each cohort and pre-imputation quality control in each study are
listed in Supplementary Table S13. In brief, genotyping was performed using
commercially available arrays. To increase the number of tested SNPs and the
overlap of variants available for analysis between different arrays, all European
ancestry cohorts imputed genotypes to the most current HRC v1.1 reference
panel57 on the Michigan Imputation Server58. GWAS was conducted in each study
under an additive genetic model using PLINK v2.059. For chromosome X, males
and females were both on a 0..2 scale (chromosome X inactivation assumption
model). Models were adjusted for population structure using the first five principal
components, sex (except in the women-only analyses) and study-specific genomic
control. Prior to meta-analysis, we removed SNPs with low minor allele frequencies
(MAF) (<0.01), low imputation quality (r2 < 0.8), and deviations from Hardy-
Weinberg equilibrium (P < 10−5). A total of 5,483,710 variants met these criteria
and were kept in the final results.
Association results were combined using an inverse variance-weighted fixed-
effects meta-analysis in METAL software60, with correction for genomic control.
Heterogeneity was assessed using the I2 metric from the complete study-level meta-
analysis. Between-study heterogeneity was tested using the Cochran Q statistic and
considered significant at P ≤ 10−3Genome-wide significance threshold was set at
the level of P= 5.0 × 10−8. LocusZoom (http://locuszoom.org/) was used to
provide regional visualization of results. Statistical analyses and plotting were
performed using R (3.6.1), through RStudio interface software (v1.2.335).
Following packages were used: MatrixEQTL_v.2.1.1, LDlinkR_1.0.2, ggrepel_0.8.2,
locuscomparer_1.0.0, coloc_3.2-1, dplyr_1.0.2, tidyr_1.1.1, RColorBrewer_1.1-2,
ggplot2_3.3.3.
eQTL and colocalization analyses. We queried the GTEx database (v8 release)61
with rsID of lead variants at FMD loci in arterial tissues for major associated genes
(permutations q value < 0.05). For each identified gene, variant-gene association
was queried in all tissues using “eQTL calculator” function on GTEx website
(https://gtexportal.org/home/). Uncharacterized non-coding transcripts were
excluded from the analysis. For colocalization, all SNP Gene associations in the 3
arterial tissues were retrieved from GTEx to compare with the FMD GWAS meta-
analysis result and the multifocal FMD GWAS meta-analysis result. We generated
colocalization plots using locuscompareR package62 and Bayesian posterior prob-
ability was calculated using coloc.abf function in R coloc package63. The H4
coefficient indicating the probability of the two traits to share a causal variant was
reported.
Gene-based and transcriptome-wide association analyses. Gene-based asso-
ciation was conducted using the MAGMA tool13, implemented in the FUMA
platform14. Locations of protein-coding genes were defined as the regions from
transcription start site to transcription stop site (default option in MAGMA).
TWAS was performed using FUSION R/python package17. Gene expression
models were precomputed from GTEx data (v7 release) and were provided by the
authors. Only genes with heritability P-value < 0.01 were used in the analysis.
Uncharacterized non-coding transcripts were excluded from the analysis. Both
tools used linkage disequilibrium information from the European panel of the 1000
Genomes phase 3. Bonferroni multiple testing correction was applied using the
p.adjust function in R (v 3.6.1).
Primary cell culture and ATAC-Seq experiments. With the exception of the
dermal fibroblast cell lines obtained under the DEFINE-FMD protocol, other
primary cells were purchased from Cell Applications (San Diego, CA) except HDF
(ATCC, Manassas, VA) and cultured with 5% CO2 in a 37 °C incubator following
manufacturer’s instructions. VSMC cells were grown in DMEM supplemented with
5% FBS, Insulin (5 µg/mL), EGF (0.5 ng/mL), bFGF (2 ng/mL) and antibiotics (all
from Thermo Fisher Scientific, Waltham, MA, USA). Cells were at passage 5 (HDF,
HCF, HCtAEC, HCAEC) or 6 (HCtASMC, HCASMC) for ATAC-Seq analyses.
Expression quantitative trait loci analysis on fibroblasts from FMD patients.
Fibroblasts of the DEFINE-FMD Study were derived from skin biopsy samples
using standard explant techniques from 83 FMD patients participating to the
genetic study as previously described3. Briefly, skin biopsy samples were dissected
into small pieces and cultured under cover slips in DMEM/F12 medium containing
20% foetal bovine serum, 1% antibiotic-antimycotic solution, 1% 200 mM L-glu-
tamine, 1% 100 mM Sodium pyruvate, and 1% MEM Non-Essential Amino Acids
(all from Life Technologies, Grand Island, NY, USA) at 37 °C in 5% CO2. Cell
culture medium was replaced every 48 h and confluent cells from passages 2–3
were used for RNA extractions.
Whole transcriptome sequencing was performed on an Illumina HiSeq2000
using single end following 100 base pair library preparation. Quality control was
performed using FASTQC (www.bioinformatics.babraham.ac.uk/projects/fastqc/)
that checks raw sequence data for per-base quality, per-sequence quality, number
of duplicate reads, number of reads with an adaptor, sequence length distribution,
per-base GC content, per-sequence GC content and Kmer content. GENCODE 29
was used as reference annotation to quantify gene and long non-coding RNA
(lncRNA) expression. Sequencing reads (fastq files) were mapped to GRCh38
human reference genome using STAR aligner (version 3.6.0c) with default
mapping parameters64. Low counts were removed by keeping genes where the
count per million is greater than 1 in at least two samples. After filtering zero and
low counts, an average of 34 million reads was retained per sample.
R package Matrix eQTL v.2.1.1 was used to compute cis-regulated eQTLs in the
cohorts of cases, controls and cases plus controls, respectively65. Age and the first
five genetics principal components were applied as covariates. Case control status
was accounted as a covariate effect for the case control pooled cohort. All cis-
regulatory SNPs were located within 1Mb of the gene by using the hg19 genome
(Ensembl Gene annotation build 75) and statistics were calculated by a
linear model.
Assay for transposase accessible chromatin (ATAC-Seq). Primary cells at
passage 5 or 6 were trypsinized, counted using a Nucleocounter NC-100 (Che-
mometec, Allerod, Denmark), and 50,000 cells were collected for each experiment.
ATAC library preparation was performed as described in the Omni-ATAC
protocol66,67. Briefly, cells were washed in PBS and incubated for 3 min in 50 µL
Resuspension Buffer (10 mM Tris-HCL, pH 7.4, 10 mM NaCl, 3 mM MgCl2, all
from Sigma-Aldrich, Saint-Louis, MI, USA) containing 0.1% Tween 20 (Sigma-
Aldrich, Saint-Louis, MI, USA), 0.1% IGEPAL CA-630 (Sigma-Aldrich, Saint-
Louis, MI, USA) and 0.01% Digitonin (Thermo Fisher Scientific, Waltham, MA,
USA), before 1 mL Resuspension Buffer with 0.1%Tween 20 was added to the cells.
After centrifugation, isolated nuclei were resuspended in Transposition Buffer
(50 µL, made from 16.5 µL PBS, 5 µL H2O, 0.5 µL Tween 20 (10%), 0.5 µL Digitonin
1%, 25 µL 2× TD Buffer and 2.5 µL TD Enzyme, last two from Illumina, San Diego,
CA, USA). Then, the transposition reaction was purified with MinElute PCR
Purification Kit (QIAGEN, Hilden, Germany). Transposed DNA was preamplified
for 5 cycles using Phusion Flash High-Fidelity PCR Master Mix (F548L, Thermo
Fisher Scientific, Waltham, MA, USA), then 10% (5 µL) of the reaction was used to
prepare a 15 µL PCR mix containing SyBR Green in order to estimate the optimal
number of amplification cycles (enough to reach between 25% and 33% of max-
imum flurorescence). Remaining 45 µL were run for the calculated number of
cycles. Amplified DNA was purified using Agencourt AMPure XP beads (Beckman
Coulter, Brea, CA), according to manufacturer’s instructions. Tagmented frag-
ments were isolated and PCR-amplified for 6–9 cycles as described previously66.
ATAC-seq libraries were sequenced using 42 paired-end sequencing cycles on an
Illumina NextSeq500 system at the high throughput sequencing core facility of
Institute for Integrative Biology of the Cell (CNRS, France, Centre de Recherche de
Gif – http://www.i2bc.paris-saclay.fr/). Reads were demultiplexed using bcl2fastq2-
2.18.12, and 31 to 95 million reads (fragments) were obtained per sample. Adaptor
sequences were trimmed using CutAdapt v1.15. Raw reads from healthy coronary
artery samples were retrieved from sequence read archive (SRR2378591,
SRR2378592, SRR2378593).
Analyses were performed on the Galaxy webserver68. Reads were mapped on
GRCh38 (hg38) genome using Bowtie2 v2.3.4.3 with default settings, except reads
could be paired at up to 2 kb distance. Aligned reads were filtered using BAM filter
v0.5.9, keeping only mapped, properly paired reads, and removing secondary
alignment and PCR duplicate reads as well as blacklisted regions69. ATAC peaks
were called using MACS2 callpeak v2.1.1.20160309.6 with default settings. Binary
read density files (bigwig) were created using bamCoverage v3.3.0.0.0, normalized
on hg38 genome.
To perform sample correlation and principal component analyses, a common
list of enriched regions was generated using bedtools multiple intersect (Galaxy
Version 2.29.0) in “cluster” mode, and average read coverage on these regions was
computed using deepTools multiBamsummary (Galaxy Version 3.3.2.0.0).
deepTools plotCoverage and plotPCA functions were used to calculate Spearman
correlation between samples and Principal Component Analysis, respectively.
Global peak annotation was performed using ChIPSeeker v1.22.070. We used
Diffbind (Galaxy Version 2.10.0) to detect differentially accessible regions between
Artery and SMC and Artery and EC samples71. Peaks enriched in arteries in both
conditions were taken as artery-specific peaks (N= 5251). clusterProfiler v3.14.0
was used to annotate genes at proximity (≤10 kb, 1425 genes) of ATAC-Seq peaks
and identify enriched gene ontology terms72. Identified GOBP terms were clustered
using REVIGO webserver (http://revigo.irb.hr/), with “medium” settings73. We
used DAVID webserver (https://david.ncifcrf.gov/) to perform functional
annotation clustering with default parameters except GO FAT categories were
added to the analysis.
Annotation with epigenomic data. We computed the overlap of variant with open
chromatin regions (narrowpeak from MACS2 output + 100 bp on each side) and
histone-ChIP peaks using bedtools (v2.29.0) annotate function. The 95% credible set
of causal variants was retrieved from LocusZoom (http://locuszoom.org/). Full list of
peak files used is available in Supplementary Table S14. Analysis of SNP enrichment
among ATAC-Seq peaks was performed using GREGOR19. The lead SNPs from loci
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associated with P value < 10−4 were used as reference for FMD-associated SNPs
(Supplementary Data 1). We included in the analysis SNPs in LD with lead SNPs
(r2 ≥ 0.7 in the European subset of the 1000 Genomes phase 3 reference panel). We
used Integrated Genome Browser (IGB, v9.1.4) to visualize read density profiles and
peak positions in the context of human genome74.
Overlap between FMD loci and other traits and diseases. We queried the
GWAS catalogue database75, UK Biobank GWAS summary statistics made publicly
available by the Neale lab at the Broad Institute (http://www.nealelab.is/uk-
biobank) and GWAS meta-analyses on blood pressure21, spontaneous coronary
artery dissection24, cervical artery dissection23, migraine22, CAD/MI26, IA/uIA/
SAH76 and Stroke77 with FMD lead SNPs and LD proxies (r2 ≥ 0.5 in the European
panel of the 1000 Genomes phase 3). We reported vascular phenotypes with at least
one variant with genome-wide (P < 5 × 10−8) or suggestive (P < 10−5) association.
Colocalization plots were generated using locuscompareR package62. Comparative
TWAS in FMD and other traits was performed using HapMap filtered summary
statistics (see below).
Heritability and genetic correlation analyses. We used LD score regression to
assess the SNP-based heritability (h2) of FMD and to estimate genetic correlation
between FMD and other diseases and traits12. Linkage disequilibrium score
regression regresses SNP GWAS χ2 statistics for FMD (to infer SNP-based herit-
ability) or χ2 statistics cross products for 2 traits (to infer Genetic correlation) on
LD scores (the sum of a SNP pairwise squared correlation with other SNPs in a
1 cM window). Summary statistics were acquired from the respective consortia and
are detailed in Supplementary Table S15. For each trait, we filtered the summary
statistics to the subset of HapMap 3 SNPs to decrease the potential for bias due to
poor imputation quality. Correlation analyses were restricted to summary statistics
from European ancestry meta-analyses. We used the European LD score files
calculated from the 1000G reference panel and provided by the developers. A
P < 1.6 × 10−3, corresponding to adjustment for 31 independent phenotypes was
considered significant. All analyses were performed with the ldsc package (v1.0.1,
https://github.com/bulik/ldsc/). We conditioned FMD association on systolic blood
pressure genetic association using multi-trait-based conditional and joint analysis
(mtCOJO) tool from GCTA pipeline78. The resulting summary statistics were then
used to calculate genetic correlation between FMD, conditioned on systolic blood
pressure, and the previous traits.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
The GWAS data generated in this study have been deposited in the GWAS catalogue
database under accession code GCST90026612. Summary statistics data used for genetic
correlation were acquired from the respective consortia and are detailed in
Supplementary Table S15. The ATAC-Seq sequencing data generated in this study are
publicly available on the Sequence Read Archive under accession code PRJNA690001.
Other genomic datasets used in these studies were retrieved from public databases and a
full list of files with accession is available in Supplementary Table S14. Fibroblast eQTL
dataset generated was looked up for identified genes only and cannot be made fully
available to protect patient’s privacy. Data accessibility will be provided upon reasonable
request to DEFINE-FMD leaders.
Code availability
Publicly available softwares and packages were used throughout this study according to
developers instruction. No custom algorithms were generated for the study. A complete
list of softwares and packages is provided in the reporting summary.
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